Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients

Metabolism: Clinical and Experimental

Volumn 59, Issue 1, 2010, Pages 64-69

  Oz Gul, Ozen ^a   Tuncel, Ercan ^a   Yilmaz, Yusuf ^b   Ulukaya, Engin ^a   Gul, Cuma Bulent ^a   Kiyici, Sinem ^a   Oral, Arzu Yilmaztepe ^a   Guclu, Metin ^a   Ersoy, Canan ^a   Imamoglu, Sazi ^a  

^a ULUDAG UNIVERSITY   (Turkey)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROGENESIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC DIET; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; PILOT PROJECTS; PLACEBOS; RECEPTORS, IMMUNOLOGIC; SOLUBILITY; THIAZOLIDINEDIONES;

EID: 72049115492     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.07.006     Document Type: Article

References (30)

1. Yan S.F., Ramasamy R., and Schmidt A.M. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 4 (2008) 285-293
2. Yan S.F., D'Agati V., Schmidt A.M., and Ramasamy R. Receptor for advanced glycation end products (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging. Curr Mol Med 7 (2007) 699-710
3. Geroldi D., Falcone C., and Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 13 (2006) 1971-1978
4. Santilli F., Vazzana N., Bucciarelli L.G., and Davì G. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem 16 (2009) 940-952
5. Hudson B.I., Harja E., Moser B., and Schmidt A.M. Soluble levels of receptor for advanced glycation end products (sRAGE) and coronary artery disease: the next C-reactive protein?. Arterioscler Thromb Vasc Biol 25 (2005) 879-882
6. Yamagishi S., Matsui T., and Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets 8 (2007) 1138-1143
7. Koyama H., Yamamoto H., and Nishizawa Y. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med 13 (2007) 625-635
8. Basta G., Sironi A.M., Lazzerini G., Del Turco S., Buzzigoli E., Casolaro A., et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 91 (2006) 4628-4634
9. Yamagishi S., and Imaizumi T. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) may reflect tissue RAGE expression in diabetes. Arterioscler Thromb Vasc Biol 27 (2007) e32
10. Devangelio E., Santilli F., Formoso G., Ferroni P., Bucciarelli L., Michetti N., et al. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med 43 (2007) 511-518
11. Cho N., and Momose Y. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress. Curr Top Med Chem 8 (2008) 1483-1507
12. Gross B., and Staels B. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Pract Res Clin Endocrinol Metab 21 (2007) 687-710
13. Marx N., Walcher D., Ivanova N., Rautzenberg K., Jung A., Friedl R., et al. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 53 (2004) 2662-2668
14. Wang K., Zhou Z., Zhang M., Fan L., Forudi F., Zhou X., et al. Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J Pharmacol Exp Ther 317 (2006) 37-43
15. Tan K.C., Chow W.S., Tso A.W., Xu A., Tse H.F., Hoo R.L., et al. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia 50 (2007) 1819-1825
16. Santilli F., Bucciarelli L., Noto D., Cefalù A.B., Davì V., Ferrante E., et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med 43 (2007) 1255-1262
17. Emanuele E., and Geroldi D. A novel mechanism of action of atorvastatin against cardiovascular risk: a commentary on "decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins". Free Radic Biol Med 43 (2007) 1231-1232
18. Forbes J.M., Thorpe S.R., Thallas-Bonke V., Pete J., Thomas M.C., Deemer E.R., et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 16 (2005) 2363-2372
19. Nakamura K., Yamagishi S., Nakamura Y., Takenaka K., Matsui T., Jinnouchi Y., et al. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res 70 (2005) 137-141
20. Erdmann E., Dormandy J.A., Charbonnel B., Massi-Benedetti M., Moules I.K., and Skene A.M. PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 49 (2007) 1772-1780
21. Home P.D., Pocock S.J., Beck-Nielsen H., Gomis R., Hanefeld M., Jones N.P., et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 357 (2007) 28-38
22. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
23. Chiquette E., Ramirez G., and Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 164 (2004) 2097-2104
24. Sakamoto J., Kimura H., Moriyama S., Odaka H., Momose Y., Sugiyama Y., et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 278 (2000) 704-711
25. Miyata T., and Izuhara Y. Inhibition of advanced glycation end products: an implicit goal in clinical medicine for the treatment of diabetic nephropathy?. Ann N Y Acad Sci 1126 (2008) 141-146
26. Yilmaz Y., Ulukaya E., Gul O.O., Arabul M., Gul C.B., Atug O., et al. Decreased plasma levels of soluble receptor for advanced glycation end products (sRAGE) in patients with nonalcoholic fatty liver disease. Clin Biochem 42 (2009) 802-807
27. Humpert P.M., Djuric Z., Kopf S., Rudofsky G., Morcos M., Nawroth P.P., et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 6 (2007) 9
28. Brown L.F., and Fraser C.G. Assay validation and biological variation of serum receptor for advanced glycation end-products. Ann Clin Biochem 45 (2008) 518-519
29. Nakamura K., Yamagishi S., Adachi H., Matsui T., Kurita-Nakamura Y., Takeuchi M., et al. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab Res Rev 24 (2008) 109-114
30. Nakamura K., Yamagishi S., Adachi H., Kurita-Nakamura Y., Matsui T., Yoshida T., et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 13 (2007) 185-189